OBIO vs T · rev $2.6M vs P/E 7.4, rev $125.65B
Orchestra BioMed Holdings Inc. (OBIO) versus AT&T Inc. (T) — a side-by-side from cached financials, not a winner call.
Orchestra BioMed Holdings Inc. (OBIO) is a biotechnology company listed on NASDAQ.
AT&T Inc. (T) is a telecom services company listed on NYSE. It is led by John Stankey.
Latest reported OBIO revenue for 2024-12-31 was $2.6M. Net income was -$61.0M. Revenue was down 4.4% from 2023-12-31 to 2024-12-31. OBIO currently screens at market cap $231.7M.
Latest reported T revenue for 2025-12-31 was $125.65B. Net income was $21.95B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. T currently screens at market cap $155.92B and trailing P/E 7.4.
OBIO currently screens at market cap $231.7M. T currently screens at market cap $155.92B and trailing P/E 7.4.
Not investment advice. Open the OBIO and T stock pages for the full models.
Not investment advice.